Literature DB >> 32945063

Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast cancer in Taiwan.

Lin-Chien Wang1, Chun-Nan Kuo1,2, Yu Ko1,3.   

Abstract

Entities:  

Keywords:  T-DM1; cost-effectiveness analysis; metastatic breast cancer

Mesh：

Substances：

Year:  2020        PMID： 32945063     DOI： 10.1111/tbj.14053

Source DB:  PubMed          Journal:  Breast J        ISSN： 1075-122X            Impact factor:   2.431


× No keyword cloud information.
  2 in total

1.  Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.

Authors:  Jiangping Yang; Jiaqi Han; Yalan Zhang; Muhelisa Muhetaer; Nianyong Chen; Xi Yan
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

2.  Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.

Authors:  Guiyuan Xiang; Lingna Gu; Xuan Chen; Fan Wang; Bohua Chen; Jie Zhao; Yun Lu; Feng Chang; Yumei Zhu
Journal:  Front Public Health       Date:  2021-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.